StockNews.com Begins Coverage on VolitionRx (NYSE:VNRX)

by · The Cerbat Gem

StockNews.com assumed coverage on shares of VolitionRx (NYSE:VNRX – Free Report) in a report issued on Friday. The brokerage issued a sell rating on the stock.

Separately, Benchmark restated a hold rating on shares of VolitionRx in a research note on Friday, August 16th.

Read Our Latest Research Report on VolitionRx

VolitionRx Stock Performance

Shares of VNRX stock opened at $0.72 on Friday. The firm has a market capitalization of $59.29 million, a PE ratio of -1.55 and a beta of 1.09. The stock has a fifty day moving average of $0.65 and a two-hundred day moving average of $0.69. VolitionRx has a 1 year low of $0.43 and a 1 year high of $1.23.

VolitionRx (NYSE:VNRX – Get Free Report) last posted its earnings results on Wednesday, August 14th. The company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.09) by $0.01. The company had revenue of $0.40 million for the quarter, compared to the consensus estimate of $0.34 million. Equities research analysts predict that VolitionRx will post -0.31 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Guy Archibald Innes acquired 150,000 shares of the stock in a transaction on Tuesday, August 20th. The shares were bought at an average price of $0.67 per share, with a total value of $100,500.00. Following the completion of the purchase, the director now owns 406,683 shares of the company’s stock, valued at approximately $272,477.61. This represents a 0.00 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 12.80% of the stock is owned by company insiders.

About VolitionRx

(Get Free Report)

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.

See Also